SCHEMBL15020592

SCHEMBL15020592

Cc1nn2c(-c3cccc(C(F)(F)F)c3)cc(N3CCCC3CO)nc2c1-c1ccc2c(c1)OCO2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ ITGB2 P05107 4/20 0.42
▸ ICAM1 P05362 4/20 0.42
▸ ITGAL P20701 4/20 0.42
▸ PLAT P00750 1/20 0.40
▸ PDCD1 Q15116 1/20 0.39
▸ CD274 Q9NZQ7 1/20 0.39
▸ CYP1A2 P05177 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ TRPV1 Q8NER1 2/20 0.37
▸ SPHK2 Q9NRA0 1/20 0.37
▸ SPHK1 Q9NYA1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020607 0.90 ITGB2 (0.39) ALDH1A1ITGB2ICAM1ITGALPDCD1
SCHEMBL15020601 0.89 ALDH1A1 (0.40) ALDH1A1KMT2AMEN1ITGB2ICAM1
SCHEMBL257516 0.89 ALDH1A1 (0.45) ALDH1A1ITGB2ICAM1ITGALHPGD
SCHEMBL15020929 0.89 ALDH1A1 (0.45) ALDH1A1ITGB2ICAM1ITGALHPGD
SCHEMBL15020591 0.89 MEN1 (0.46) ALDH1A1KMT2AMEN1ITGB2ICAM1
SCHEMBL15020578 0.89 LMNA (0.40) ALDH1A1KMT2AMEN1ITGB2ICAM1
SCHEMBL256817 0.89 KMT2A (0.45) ALDH1A1KMT2AMEN1ITGB2ICAM1
SCHEMBL15021376 0.89 KMT2A (0.45) ALDH1A1KMT2AMEN1ITGB2ICAM1
SCHEMBL15042205 0.88 MEN1 (0.46) ALDH1A1KMT2AMEN1ITGB2ICAM1
SCHEMBL15020906 0.88 ALDH1A1 (0.40) ALDH1A1KMT2AMEN1ITGB2ICAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US claimed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP claimed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US claimed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 ALDH1A1 2139/4885KMT2A 2428/4885MEN1 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback